Details of the Drug

General Information of Drug (ID: DMF86P2)

Drug Name
BI 655064
Indication
Disease Entry ICD 11 Status REF
Lupus 4A40 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 1 [2]
Thrombocytopenia 3B64 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0C8NG
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD40L receptor (CD40) TTN6Y9A TNR5_HUMAN Inhibitor [1]
TNF related activation protein (CD40LG) TTIJP3Q CD40L_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 03 Disease of the blood or blood-forming organs
Disease Class ICD-11: 3B64 Thrombocytopenia
The Studied Tissue Whole blood
The Studied Disease Thrombocytopenia [ICD-11:3B64]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD40L receptor (CD40) DTT CD40 4.61E-01 0.56 0.5
TNF related activation protein (CD40LG) DTT CD40LG 3.90E-01 0.04 0.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02009761) Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).. U.S. National Institutes of Health.
3 FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study